Rivfloza: Dosage Form, Projected Sales, NCE-1 Date | Nedosiran

Rivfloza

Rivfloza is a once-monthly injection for children more than 2 years old and adults with primary hyperoxaluria type 1. It lowers urine oxalate levels by silencing a liver enzyme, helping protect kidney function.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Nedosiran
Innovator :

NOVO NORDISK INC
Approval Date :

29-Sep-23
NCE-1 Date :

29-Sep-27
NCE Date :

29-Sep-28
Dosage Form :

Injection
Strength :

80mg base /0.5ml, 128mg base/ 0.8ml, 160mg base/ 1ml
Therapeutic Category :

Antimetabolic Disorder
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

89
2026 :

141
2027 :

190
2028 :

216
2029 :

233
2030 :

242
2031 :

253

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Rivfloza

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?